Vinaxanthone (SM-345431) (0.1 mg/mL, Subconjunctival injections, every 2 days, 3 weeks) accelerates peripheral nerve regeneration and sensitivity in a murine corneal transplantation model[4].
Vinaxanthone (SEMA3A-I) (20 μg, i.p.) protects from Doxorubicin (HY-15142A)-induced podocyte injury through an anti-apoptosis mechanism in mouse model of Doxorubicin (HY-15142A)-induced podocytopathy[5].
| Animal Model: | murine corneal transplantation model[4] |
| Dosage: | 0.1 mg/mL |
| Administration: | Subconjunctival injections, every 2 days, 3 weeks |
| Result: | Showed significantly higher nerve growth.
Improved the corneal sensitivity.
|
| Animal Model: | mouse model of Doxorubicin (10 mg/kg)-induced podocytopathy[5] |
| Dosage: | 20 μg |
| Administration: | Intraperitoneal injection (i.p.), every day |
| Result: | Improved the expression of nephrin.
Reduced podocytopathy and tubular casts.
Detected rarely TUNEL-positive cells in the Dox + Vinaxanthone group.
Had fewer p-c-Jun-positive cells in the Dox + Vinaxanthone group.
|
